Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss.
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash deal, valued at $14.00 per share, marks
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic Labs, this model has fundamentally shifted the paradigm of biological research. While its predecessor famously solved the 50-year-old protein-folding problem, AlphaFold 3 has gone significantly [...]
Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss.
In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx Biosciences (NASDAQ: VTYX) for approximately $1.2 billion. The all-cash deal, announced in early January 2026, values Ventyx at $14.00
In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a target and stop a disease in its tracks. However, a seismic shift occurred with the maturation of AlphaProteo, a generative AI [...]
Mid-January is bringing a sharper read on investors’ willingness to fund high-risk science, and Carvina Capital Pte. Ltd. is following the message as Aktis Oncology opens the market for sizeable biotechnology flotations with a radiopharmaceutical listing that tests both price and patience.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
